Literature DB >> 1185570

Comparative bioavailabilities from truncated blood level curves.

E G Lovering, I J McGilveray, I McMillan, W Tostowaryk.   

Abstract

The period of time after administration over which blood level measurements are required to obtain a reliable bioavailability comparison of two or more formulations of the same drug was considered by the analysis of bioavailability data taken from the literature. The drugs examined, selected to represent a range of absorption and elimination half-lives, were acetaminophen, aminosalicylic acid, chloramphenicol, chlordiazepoxide, digoxin, isoniazid, phenylbutazone, sulfamethizole, tetracycline, and warfarin. For most drugs, ratios of areas under the curve changed little between the end of the absorption period and the time when blood sampling was terminated. Reliable bioavailability comparisons among different brands of the drugs apparently could have been made by blood sampling over 24 hr or less.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185570     DOI: 10.1002/jps.2600640921

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.

Authors:  P Sathe; J Venitz; L Lesko
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF).

Authors:  M N Martinez; A J Jackson
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

3.  Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations.

Authors:  J Gaudreault; D Potvin; J Lavigne; R L Lalonde
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

4.  Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

Authors:  J G Wagner; J W Ayres
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

5.  Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique.

Authors:  P J Morrison; I D Bradbrook; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

6.  Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.

Authors:  D A Lee; G M Taylor; V H James; G Walker
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

7.  Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models.

Authors:  Pavlos Chryssafidis; Athanasios A Tsekouras; Panos Macheras
Journal:  Pharm Res       Date:  2022-04-04       Impact factor: 4.200

8.  Disposition of chloroquine in man after single intravenous and oral doses.

Authors:  L L Gustafsson; O Walker; G Alván; B Beermann; F Estevez; L Gleisner; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

9.  Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man.

Authors:  D M Cocchetto; S M Owens; M Perez-Reyes; S DiGuiseppi; L L Miller
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.